Rida Shah, MD
Internal Medicine · Plymouth Meeting, PANPI 1063892255
Payments from drug & device makers
Across 7 payments — averaging $29.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$45
- Teva Pharmaceuticals USA, Inc.$44
- Acadia Pharmaceuticals Inc$42
- Vapotherm Inc$34
- Sunovion Pharmaceuticals Inc.$25
- Neurocrine Biosciences, Inc.$18
What the payments were for
- Food & beverage$208100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 1 | $45 |
| Teva Pharmaceuticals USA, Inc. | 1 | $44 |
| Acadia Pharmaceuticals Inc | 2 | $42 |
| Vapotherm Inc | 1 | $34 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
How this compares
$208 in reported general payments places this provider in the 50th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 191 | $54,261 |
| JanuviaSitagliptin Phosphate | 37 | $17,235 |
| EntrestoSacubitril/Valsartan | 55 | $14,756 |
| JardianceEmpagliflozin | 27 | $13,940 |
| XareltoRivaroxaban | 26 | $6,317 |
| Baclofen | 101 | $5,800 |
| MovantikNaloxegol Oxalate | 13 | $5,325 |
| Atorvastatin Calcium | 470 | $5,265 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,245 |
| Darifenacin ErDarifenacin Hydrobromide | 14 | $3,431 |
| Levetiracetam | 79 | $3,388 |
| Enoxaparin Sodium | 14 | $2,458 |
| Gabapentin | 134 | $2,199 |
| Tamsulosin Hcl | 125 | $2,124 |
| Metoprolol Succinate | 153 | $2,044 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Plymouth Meeting
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.